Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benfotiamine in Alzheimer's Disease
NCT02292238Phase 2Completed
- Sponsor
- Burke Neurological Institute
- Start
- Feb 2015
- Primary completion
- Jul 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) and amnestic mild cognitive impairment (MCI) comparing Benfotiamine with Placebo (2 arms). Primary endpoint: Alzheimer's Disease Assessment Scale-Cognitive Subscale at 1 year. Started Feb 2015; status: completed.
02
Drugs
benfotiamine
03
Conditions
Alzheimer's disease (AD)amnestic mild cognitive impairment (MCI)
Beyond the preview
Go deeper on NCT02292238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02292238.